Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
(WorldNews Health)

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company`s ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with specific subtypes of T-cell Non-Hodgkin Lymphoma, including relapsed/refractory peripheral T-cell lymphoma (PTCL); angioimmunoblastic T-cell lymphoma (AITL), a subset of PTCL; and cutaneous T-cell lymphoma (CTCL). The data will be presented today during an oral session at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando (December 7-10). As of the November 12, 2019 cut-off date, 64 PTCL patients and 40 CTCL...